Combination Regimens (Imdusiran-based)

About Arbutus Biopharma

Arbutus Biopharma is a pure-play virology company with a mission to achieve a functional cure for chronic hepatitis B (HBV). Its core strategy is a multi-mechanistic combination approach, anchored by its RNAi therapeutic imdusiran, which has demonstrated meaningful functional cure rates in clinical trials. The company is led by a newly appointed, transaction-savvy leadership team with deep expertise in building and scaling biotech ventures. Arbutus's concentrated focus on the large, underserved HBV market positions it as a key contender in the race for a curative regimen.

Therapeutic Areas

Other Chronic Hepatitis B (cHBV) Drugs